FDA raids California offices of e-cigarette maker

The Food and Drug Administration conducted a surprise inspection at the offices of Juul Labs—a large e-cigarette maker—last week and walked away with more than a thousand pages of documents related to the company’s marketing and sales practices, The New York Times reported.

Juul, which controls 72 percent of the e-cigarette market, has recently come under fire for allegedly marketing its products to underage teenagers, and its products have become widely popular in U.S. high schools.

“The new and highly disturbing data we have on youth use demonstrates plainly that e-cigarettes are creating an epidemic of regular nicotine use among teens,” the FDA said in a statement. “It is vital that we take action to understand and address the particular appeal of, and ease of access to, these products among kids.”

The raid marks a significant ramp up in pressure on the e-cigarette market as concerns mount over the rapid increase of vaping among youths. About 3 million high school students said they used e-cigarettes within the last 30 days, a jump of 75 percent since last year, according to one recent study. Teenagers who start vaping, or using e-cigarettes, are more likely to smoke traditional cigarettes, other studies show.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.